185 related articles for article (PubMed ID: 36748923)
1. Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high-risk infants.
Stiboy E; Chan M; Islam MS; Saravanos GL; Lui K; Jaffe A; Homaira N
Pediatr Pulmonol; 2023 Apr; 58(4):1210-1220. PubMed ID: 36748923
[TBL] [Abstract][Full Text] [Related]
2. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK.
Narayan O; Bentley A; Mowbray K; Hermansson M; Pivonka D; Kemadjou EN; Belsey J
J Med Econ; 2020 Dec; 23(12):1640-1652. PubMed ID: 33107769
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia.
Ordóñez JE; Huertas VM
BMC Infect Dis; 2024 Apr; 24(1):418. PubMed ID: 38641577
[TBL] [Abstract][Full Text] [Related]
4. A Systematic Review of European Clinical Practice Guidelines for Respiratory Syncytial Virus Prophylaxis.
Reeves RM; van Wijhe M; Lehtonen T; Stona L; Teirlinck AC; Vazquez Fernandez L; Li Y; Osei-Yeboah R; Fischer TK; Heikkinen T; van Boven M; Bøås H; Donà D; Barbieri E; Campbell H;
J Infect Dis; 2022 Aug; 226(Suppl 1):S110-S116. PubMed ID: 35333332
[TBL] [Abstract][Full Text] [Related]
5. A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children.
Ambrose CS; Chen X; Kumar VR
Hum Vaccin Immunother; 2014; 10(10):2785-8. PubMed ID: 25483483
[TBL] [Abstract][Full Text] [Related]
6. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
Wang D; Bayliss S; Meads C
Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
Frogel MP; Stewart DL; Hoopes M; Fernandes AW; Mahadevia PJ
J Manag Care Pharm; 2010; 16(1):46-58. PubMed ID: 20131495
[TBL] [Abstract][Full Text] [Related]
8. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.
Oh PI; Lanctôt KL; Yoon A; Lee DS; Paes BA; Simmons BS; Parison D; Manzi P;
Pediatr Infect Dis J; 2002 Jun; 21(6):512-8. PubMed ID: 12182374
[TBL] [Abstract][Full Text] [Related]
9. RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study.
Xu R; Fathima P; Strunk T; de Klerk N; Snelling TL; Richmond PC; Keil AD; Moore HC
BMC Pediatr; 2020 Oct; 20(1):490. PubMed ID: 33092566
[TBL] [Abstract][Full Text] [Related]
10. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.
Pediatrics; 1998 Nov; 102(5):1211-6. PubMed ID: 9794957
[TBL] [Abstract][Full Text] [Related]
11. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
12. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
Meissner HC; Long SS;
Pediatrics; 2003 Dec; 112(6 Pt 1):1447-52. PubMed ID: 14654628
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for hospitalisation due to respiratory syncytial virus infection in children receiving prophylactic palivizumab.
Chida-Nagai A; Sato H; Sato I; Shiraishi M; Sasaki D; Izumi G; Yamazawa H; Cho K; Manabe A; Takeda A
Eur J Pediatr; 2022 Feb; 181(2):539-547. PubMed ID: 34417646
[TBL] [Abstract][Full Text] [Related]
14. Access to palivizumab among children at high risk of respiratory syncytial virus complications in English hospitals.
Zylbersztejn A; Almossawi O; Gudka N; Tompsett D; De Stavola B; Standing JF; Smyth R; Hardelid P
Br J Clin Pharmacol; 2022 Mar; 88(3):1246-1257. PubMed ID: 34478568
[TBL] [Abstract][Full Text] [Related]
15. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.
Fenton C; Scott LJ; Plosker GL
Paediatr Drugs; 2004; 6(3):177-97. PubMed ID: 15170364
[TBL] [Abstract][Full Text] [Related]
16. Effect of Prophylactic Palivizumab on Admission Due to Respiratory Syncytial Virus Infection in Former Very Low Birth Weight Infants with Bronchopulmonary Dysplasia.
Han YM; Seo HJ; Choi SH; Jung YJ; Ahn SY; Yoo HS; Sung SI; Shim JW; Lee YK; Ko SY; Shin SM; Hwang JH; Lee JH; Choi BM; Kim ES; Jeon JH; Kim SS; Chang YS; Park WS
J Korean Med Sci; 2015 Jul; 30(7):924-31. PubMed ID: 26130956
[TBL] [Abstract][Full Text] [Related]
17. Prolonged seasonality of respiratory syncytial virus infection among preterm infants in a subtropical climate.
Hsu CH; Lin CY; Chi H; Chang JH; Hung HY; Kao HA; Peng CC; Jim WT
PLoS One; 2014; 9(10):e110166. PubMed ID: 25333346
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .
Lanctôt KL; Masoud ST; Paes BA; Tarride JE; Chiu A; Hui C; Francis PL; Oh PI
Curr Med Res Opin; 2008 Nov; 24(11):3223-37. PubMed ID: 18928643
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
[TBL] [Abstract][Full Text] [Related]
20. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
Oncel MY; Mutlu B; Kavurt S; Baş AY; Demirel N; Akyol M; Erdeve O; Dilmen U
Turk J Pediatr; 2012; 54(4):344-51. PubMed ID: 23692714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
